Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
pirfenidone (esbriet) (3 trials)
triamcinolone (kenalog) (1 trial)
Albuminuria (Phase 3)
Alveolitis, Extrinsic Allergic (Phase 3)
Diabetic Nephropathies (Phase 3)
Hypersensitivity (Phase 3)
Keloid (Phase 3)
Kidney Diseases (Phase 3)
Pneumonia (Phase 3)
Pulmonary Fibrosis (Phase 3)
Trials (3 total)
Trial APIs (2 total)